MALVERN, PA – June 21 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (“RBC” – www.reactionbiology.com) today announced that it has been awarded a Phase I SBIR grant from the National Institutes of Health to develop its new microarray kinase screening technology for testing compounds in nanoliter reactions.
The grant funds the use of RBC’s DiscoveryDot(tm) microarray technology for high throughput screening of kinases. The DiscoveryDot(tm) technology is capable of screening up to 6600 individual reactions on a 1-by-3 inch glass slide. Its one nanoliter reaction volume is one ten thousandth the volume of conventional screening systems, and can potentially save millions of dollars on large scale screening campaigns through reagent savings, labor reduction, and multiple compound library printing.
Protein kinases play pivotal roles in signal transduction and represent one of the most studied targets in the pharmaceutical and biotechnology industry, particularly with respect to cancer or inflammation therapy. The ability to print large chemical libraries in hundreds of replicate sets for kinase and phosphatase screening can drive chemical-proteomic research, environmental toxicology, hit discovery and prioritization, and lead selection. RBC plans to expand its assay range across the human kinome using the DiscoveryDot(tm) assay.
About Reaction Biology Corporation
Reaction Biology, based in Malvern, Pa., provides high throughput screening services to the biotechnology and pharmaceutical industry. The company uses a patent-pending combination of technologies to perform screening at the nanoliter scale, while preserving quality, speed and simplicity. Combining genomics microarray printing technology and picoliter aerosol deposition, RBC has commercialized a novel technology that drives HTS to new levels of simplicity and efficiency.
More information: www.reactionbiology.com
News issued by: Reaction Biology Corporation
# # #
Original Story ID: (497) :: 2005-06-0621-001
Original Keywords: Reaction Biology Corporation, kinase, high throughput screening, microarray, RBC, Phase I SBIR grant, National Institutes of Health, microarray kinase screening technology, DiscoveryDot, pharmaceutical and biotechnology industry Reaction Biology Corporation
News Source: Reaction Biology Corporation